Suven Life bags patents for CNS drug in India and South Africa

The Hyderabad-based Suven Life Sciences Ltd has received two product patents in India and South Africa for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. Patents in India and South Africa will be valid through 2028 and 2032 respectively, said the company in a press release.

The granted claims of the patents are from the mechanism of action include the class of selective 5-HT6 compounds and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and 

Schizophrenia.

With these new patents, Suven has a total of 18 granted patents from India and 23 granted patents from South Africa.